Menu
Search
|

Menu

Close
X

Biocept Inc BIOC.OQ (NASDAQ Stock Exchange Capital Market)

2.26 USD
-0.08 (-3.42%)
As of Oct 19
chart
Previous Close 2.34
Open 2.50
Volume 144,055
3m Avg Volume 98,677
Today’s High 2.56
Today’s Low 2.21
52 Week High 36.00
52 Week Low 2.08
Shares Outstanding (mil) 3.04
Market Capitalization (mil) 7.25
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.33 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
5
FY16
3
FY15
1
EPS (USD)
FY18
-5.604
FY17
-21.517
FY16
-65.190
FY15
-96.704
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
1.94
6.55
Price to Book (MRQ)
vs sector
2.15
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
81.36
14.15
LT Debt to Equity (MRQ)
vs sector
42.03
11.31
Return on Investment (TTM)
vs sector
-336.91
12.83
Return on Equity (TTM)
vs sector
-433.16
14.95

EXECUTIVE LEADERSHIP

David Hale
Non-Executive Chairman of the Board, Since 2014
Salary: $111,289.00
Bonus: --
Michael Nall
President, Chief Executive Officer, Director, Since 2013
Salary: $362,202.00
Bonus: $101,500.00
Timothy Kennedy
Chief Financial Officer and Senior Vice President of Operations, Since 2016
Salary: --
Bonus: --
Lyle Arnold
Senior Vice President - Research & Development, Chief Scientific Officer, Since 2011
Salary: $261,672.00
Bonus: $59,867.00
Edwin Hendrick
Senior Vice President, Chief Commercial Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Medical Equipment, Supplies & Distribution
Address:

5810 Nancy Ridge Dr Ste 150
SAN DIEGO   CA   92121-2840

Phone: +1858.3208200

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

SPONSORED STORIES